Oncology Expert Insights

Sikander Ailawadhi, MD, consultant, Division of Hematology/Oncology, Department of Internal Medicine, consultant, Department of Cancer Biology, professor, medicine, Mayo Clinic; Beth Faiman, PhD, MS, APN-BC, BMTCN, AOCN, FAAN, FAPO nurse practitioner, Multiple Myeloma Program, Cleveland Clinic

Patient-Reported Outcomes Show Benefits of Isatuximab On-Body Injector in Myeloma: With Sikander Ailawadhi, MD, and Beth Faiman, PhD, MS, APN-BC, BMTCN, AOCN, FAAN, FAPO

BySikander Ailawadhi, MD,Beth M. Faiman, PhD, MS, APN-BC, BMTCN, AOCN, FAAN, FAPO

November 5th 2025

Ailawadhi and Faiman discuss the rationale for efforts to bring isatuximab on-body injectors into the clinic for patients with multiple myeloma.

Neal Shore, MD, FACS, medical director, Carolina Urologic Research Center

Ongoing ADT Use and Research Emphasizes the Importance of Shared Decision-Making in Prostate Cancer Care: With Neal Shore, MD, FACS

ByNeal Shore, MD, FACS

October 31st 2025

Dr Shore discusses the use of ADT in patients with prostate cancer, as well as toxicities and quality-of-life complications associated with these agents.

Ziad Hanhan, MD, thoracic surgeon, Hackensack Meridian Health, chairman, Surgery at Bayshore Medical Center, chief, Thoracic Surgery, Riverview Medical Center; Thomas Bauer, MD, chair, surgery, Jersey Shore University Medical Center and Hackensack Meridian Health School of Medicine; Rachel NeMoyer, MD, thoracic surgeon, Hackensack Meridian Health

Early Detection, Surgical Innovation, and Multidisciplinary Collaboration Evolve Lung Cancer Care: With Ziad Hanhan, MD, Thomas Bauer, MD, and Rachel NeMoyer, MD

ByZiad Hanhan, MD,Thomas Bauer, MD,Rachel NeMoyer, MD

October 30th 2025

Drs Hanhan, Bauer, and NeMoyer discuss the ins and outs of lung cancer diagnosis, surgical management, and evolving treatment paradigms.

Evolving Research Paradigms, Real-World Data, and Multidisciplinary Collaboration Enhance Bladder Cancer Management: With Amit Mehta, MD

ByAmit Mehta, MD

October 29th 2025

Amit Mehta, MD, discusses practice-changing urothelial carcinoma data that have been presented throughout 2024 and 2025.

Eunice Wang, MD, professor, oncology, leader, Leukemia Clinical Disease Team, chief, leukemia, Department of Medicine, assistant member, Tumor Immunology Program, Department of Immunology, Roswell Park Comprehensive Cancer Center; associate professor, Department of Medicine, academic scholar, Jacobs School of Medicine and Biomedical Sciences, State University of New York at Buffalo

Evolving Treatment Strategies and Novel Therapies Reshape Secondary AML Management: With Eunice Wang, MD

ByEunice Wang, MD

October 22nd 2025

Dr Wang discusses the prevalence of secondary AML, unmet needs for patients with this disease, and how CPX-351 has generated improved outcomes vs 7+3.

Kanwal P. S. Raghav, MBBS, MD, professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine; associate vice president, Department of Ambulatory Medical Operations; executive medical director, Department of Ambulatory Treatment Centers, The University of Texas MD Anderson Cancer Center

Sequencing, Efficacy, and Safety Data May Further Evolve the Role of Fruquintinib in CRC: With Kanwal P. S. Raghav, MBBS, MD

ByKanwal Raghav, MBBS, MD

October 6th 2025

Dr Raghav discusses the role of fruquintinib in the treatment of adult patients with pretreated, metastatic colorectal cancer.

Stephen Liu, MD, associate professor, medicine, Georgetown University; director, Thoracic Oncology, head, Developmental Therapeutics, Georgetown Lombardi Comprehensive Cancer Center

Early Biomarker Testing Optimizes Tepotinib Use in NSCLC With MET Exon 14 Skipping Mutations: With Stephen Liu, MD

ByStephen Liu, MD

October 1st 2025

Dr Liu discusses the 2 VISION trial of tepotinib for NSCLC harboring MET exon 14 skipping alterations, as well as the importance of biomarker testing.

Expanding JAK Inhibitor Use Offers Increased Treatment Options for Cytopenic Myelofibrosis: With Andrew Kuykendall, MD

ByAndrew Kuykendall, MD

September 29th 2025

Andrew Kuykendall, MD, provides an overview of the myelofibrosis treatment paradigm.

Early CAR T-Cell Therapy Data Highlight Therapeutic Potential and Emerging Challenges in GI Cancers: With Kohei Shitara, MD

ByKohei Shitara, MD, National Cancer Center Hospital East

September 25th 2025

Kohei Shitara, MD, discusses optimizing treatment strategies and addressing unmet needs in resectable gastric and gastroesophageal junction cancers.

Asad Dean, MD, physician, Texas Oncology-Fort Worth Cancer Center

The Evolving Role of Noncovalent BTK Inhibition Informs CLL Treatment Selection: With Asad Dean, MD

ByAsad Dean, MD

September 24th 2025

Dean discusses the role of BTK inhibitors in the management of CLL and the importance of molecular profiling for treatment rechallenge decisions.

Patient Characteristics and Disease Factors Guide the Use of Dostarlimab in Recurrent Endometrial Cancer: With Dana M. Chase, MD

ByDana Chase, MD

September 17th 2025

Dana M. Chase, MD, discusses the management of recurrent endometrial cancer, emphasizing the importance of biomarker profiles and previous therapies.

Evelyn Y. Wong, MD, consultant medical oncologist specializing in gastrointestinal cancers, National Cancer Centre Singapore

Cohort Analysis Shows Importance of Early-Onset CRC Awareness and Investigation: With Evelyn Y. Wong, MD

ByEvelyn Y.T. Wong, MD

September 15th 2025

Dr Wong discusses the growing challenge of early-onset colorectal cancer and the insights from a recent cohort analysis conducted in Singapore.

John N. Allan, MD, associate professor, clinical medicine, member, lymphoma faculty, Division of Hematology and Medical Oncology, member, CLL Research Center, Weill Cornell Medicine; Melissa Rubianes, hematology/oncology physician assistant, Weill Cornell

Patient Characteristics and Care Team Collaboration Influence Treatment Decision-Making in CLL: With John N. Allan, MD; and Melissa Rubianes

ByJohn Allan, MD, Weill Cornell Medicine

September 11th 2025

Allan and Rubianes discuss factors that influence treatment decision-making for patients with chronic lymphocytic leukemia.

Balazs Halmos, MD, MS, professor, Department of Oncology (Medical Oncology), Department of Medicine (Oncology and Hematology), director, Thoracic Oncology, associate director, Clinical Science, Montefiore Einstein Comprehensive Cancer Center

Tepotinib Efficacy and Safety Profiles Underscore the Importance of Biomarker-Directed Decision-Making in NSCLC: With Balazs Halmos, MD, MS

ByBalazs Halmos, MD, MS

September 9th 2025

Dr Halmos discusses the VISION trial, the significance of MET exon 14 skipping mutations in NSCLC, and the clinical utility of tepotinib in this disease.

Tanya B. Dorff, MD, section chief, Genitourinary Disease Program, professor, Department of Medical Oncology & Therapeutics Research, City of Hope

Safety and Quality-of-Life Considerations Shape ADT Use in Prostate Cancer: With Tanya B. Dorff, MD

ByTanya B. Dorff, MD

September 2nd 2025

Dr Dorff discusses the role of ADT in prostate cancer management, how this class has evolved, and the use of relugolix across treatment settings.

Aaron Logan, MD, PhD, associate professor, clinical medicine in the Division of Hematology/Oncology, University of California, San Francisco (UCSF) School of Medicine, member, UCSF Helen Diller Family Comprehensive Cancer Center; Bijal Shah, MD, MS, associate member, Department of Malignant Hematology, Moffitt Cancer Center

Obe-Cel Data Are Poised to Refine and Expand the ALL Treatment Paradigm: With Aaron Logan, MD, PhD; and Bijal Shah, MD, MS

ByAaron Logan, MD, PhD,Bijal Shah, MD, MS

August 26th 2025

Drs Logan and Shah discussed where obe-cel currently fits into the B-ALL treatment paradigm and how the use of this agent might expand going forward.

SUPRAME Trial Propels the Development of TCR-Based Therapy in Cutaneous Melanoma: With Jason Luke, MD

ByJason Luke, MD

August 25th 2025

Dr Luke discusses the rationale for evaluating IMA203 in cutaneous melanoma and what the PRAME trial findings may mean for the future of TCR therapy.

Refining First-Line Immunotherapy Strategies in Hepatocellular Carcinoma: With Masatoshi Kudo, MD, PhD

ByMasatoshi Kudo, MD, PhD

August 21st 2025

Masatoshi Kudo, MD, discusses the evolving treatment landscape in HCC and how recent comparative analyses are helping refine the use of first-line immunotherapy-based regimens.

Ronan J. Kelly, MD, MBA, FASCO, director, Charles A. Sammons Cancer Center, chief science officer, Baylor University Medical Center, W.W. Caruth Jr. Endowed Chair of Immunology, Baylor University Medical Center, chief, Oncology, Baylor Scott & White Health System, founder and medical director, Texas Cancer Interception Institute, clinical professor, Texas A&M University College of Medicine, adjunct associate professor, oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins, professor, Clinical Sciences Division, Translational Genomics Research Institute; Michelle Shiller, DO, AP/CP, MGP, molecular genetic pathologist, Baylor University Medical Center

Multidisciplinary Collaboration Gives Forward Momentum to HER2 IHC Testing in NSCLC: With Ronan J. Kelly, MD, MBA, FASCO; and Michelle Shiller, DO, AP/CP, MGP

ByRonan J. Kelly, MD, MBA, FASCO,Michelle Shiller, DO

August 19th 2025

Drs Kelly and Shiller discuss the importance of performing IHC testing for HER2 in NSCLC and recommendations for IHC testing implementation in practice.

Exploring NCCN Guideline Updates and Advancing Immunotherapy Strategies in Nasopharyngeal Carcinoma: With Neal S. Akhave, MD

By Neal S. Akhave, MD

August 14th 2025

Neal S. Akhave, MD, discusses the addition of toripalimab to the NCCN guidelines for nasopharyngeal carcinoma.

Advancing Treatment Strategies and Real-World Perspectives for mCRC and GI Neuroendocrine Neoplasms; With Rocío García-Carbonero, MD, PhD

ByRocio Garcia-Carbonero, MD, PhD

August 12th 2025

Rocío García-Carbonero, MD, PhD, discusses trends in colorectal cancer and other gastrointestinal malignancies, presented at the 2025 ESMO GI Cancers Congress.

The European Approval of Mirdametinib Expands the Treatment Paradigm for NF1-Associated Plexiform Neurofibromas: With Ignacio Blanco, MD, PhD

By Ignacio Blanco, MD, PhD

August 7th 2025

Ignacio Blanco, MD, PhD, discusses the EU marketing authorization of mirdametinib for patients with symptomatic, inoperable plexiform neurofibromas.

The Role of Combination Checkpoint Blockade Is Evolving in MSI-H mCRC: With Elena Élez, MD, PhD

ByElena Élez, MD, PhD

August 6th 2025

Elena Élez, MD, PhD, discusses the evolving role of immunotherapy for patients with microsatellite instability–high metastatic colorectal cancer.

Retrospective Data Highlight Improved Efficacy With Maintenance Therapy vs Treatment Breaks in mCRC: With Connie Lai, MD

ByConnie Lai, MD

July 31st 2025

Connie Lai, MD, discusses a retrospective, dual-center study examining post-induction treatment strategies in metastatic colorectal cancer.

Joshua K. Sabari, MD, assistant professor, Department of Medicine, New York University Grossman School of Medicine; director, High Reliability Organization Initiatives, Perlmutter Cancer Center

Telisotuzumab Vedotin Represents a New Treatment Development for c-Met–Overexpressing NSCLC: With Joshua K. Sabari, MD

ByJoshua K. Sabari, MD

July 24th 2025

Dr Sabari highlights key research investigating telisotuzumab vedotin in patients with c-Met–overexpressing non–small cell lung cancer.

Isatuximab-Based Triplet Delivered via On-Body System Shows Promise in RRMM: With Xavier Leleu, MD, PhD; and Beth Faiman, PhD, MSN, APN-BC

ByBeth M. Faiman, PhD, MS, APN-BC, BMTCN, AOCN, FAAN, FAPO,Xavier Leleu, MD, PhD

July 21st 2025

Xavier Leleu, MD, PhD, and Beth Faiman, PhD, MSN, APN-BC, BMTCN, AOCN, FAAN, FAPO, discuss key data from the phase 3 IRAKLIA study.

Arndt Vogel, MD, faculty member, University of Toronto Institute of Medical Science, scientist, Toronto General Hospital Research Institute, medical oncologist, UHN–Princess Margaret Cancer Centre

European Approval of Zanidatamab Expands Treatment Options for HER2+ Biliary Tract Cancer: With Arndt Vogel, MD

ByArndt Vogel, MD

July 17th 2025

Dr Vogel highlights the importance of the European Commission’s approval of zanidatamab for previously treated, metastatic HER2+ biliary tract cancer.

Justine Bruce, MD, faculty member, Division of Hematology, Medical Oncology and Palliative Care, Department of Medicine, University of Wisconsin; director, VA Medical Oncology Clinical Research Program, chair, Protocol Review and Monitoring Committee, University of Wisconsin Carbone Cancer Center

Toripalimab Plus De-Intensified Chemo Represents the Potential Future of Nasopharyngeal Cancer Management: With Justine Bruce, MD

ByJustine Yang Bruce, MD

July 10th 2025

Dr Bruce discusses treatment strategies for nasopharyngeal cancer, including how first-line toripalimab plus chemotherapy has shown improved OS.

Justin Moser, MD, associate clinical investigator, melanoma and cutaneous oncology specialist, phase 1 trialist, HonorHealth Research Institute; research associate professor, Arizona State University School of Medicine and Advanced Medical Engineering

IMA203 Emerges as a Novel Investigational Agent in Cutaneous Melanoma: With Justin Moser, MD

ByJustin Moser, MD

June 30th 2025

Justin Moser, MD, discusses the ongoing phase 3 SUPRAME trial investigating IMA203 in previously treated, unresectable or metastatic cutaneous melanoma.

Misako Nagasaka, MD, PhD, associate professor, Division of Hematology and Oncology, Division of Medicine, University of California Irvine School of Medicine

T-DXd's Efficacy Stands Strong and Supports IHC Testing in HER2-Mutated NSCLC: With Misako Nagasaka, MD, PhD

ByMisako Nagasaka, MD, PhD

June 25th 2025

Dr Nagasaka discusses the evolving use of T-DXd for HER2-mutated NSCLC in light of the emergence of investigational agents in this setting.